Erowid.org: Erowid Reference 8746 : Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated with Life-threatening Diseases : Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R

Erowid References Database

Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R. “Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated with Life-threatening Diseases”. Journal of Nervous and Mental Disease. 2014. <a name="ref">Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R.</a> <a href="/references/8746">"Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated with Life-threatening Diseases"</a> <i>Journal of Nervous and Mental Disease</i>. 2014.
Text Abstract (this page) Full Text - English (526 K) Show Articles by Gasser P Holstein D Michel Y Doblin R Yazar-Klosinski B Passie T Brenneisen R Article IDs Erowid RefID: 8746 PubMedID: unknown Collections Hofmann Collection MDMA Collection All References	Abstract A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with lifethreatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 Kg of LSD (n = 8) or 20 Kg of LSD with an open-label crossover to 200 Kg of LSD after the initial blinded treatment was unmasked (n = 4). At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety ( p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced ( p = 0.021) with an effect size of 1.2, with no acute or chronic adverse effects persisting beyond 1 day after treatment or treatment-related serious adverse events. STAI reductions were sustained for 12 months. These results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted.
Comments and Responses to this Article #
Status: display earth Mar 4, 2014 16:41	New York Times Coverage of This Research # http://www.nytimes.com/2014/03/04/health/lsd-reconsidered-for-therapy.html?_r=0 - March 3, 2014 The NYTimes writes: On Tuesday, The Journal of Nervous and Mental Disease is posting online results from the first controlled trial of LSD in more than 40 years. The study, conducted in the office of a Swiss psychiatrist near Bern, tested the effects of the drug as a complement to talk therapy for 12 people nearing the end of life, including Peter. Most of the subjects had terminal cancer, and several died within a year after the trial — but not before having a mental adventure that appeared to have eased the existential gloom of their last days. “Their anxiety went down and stayed down,” said Dr. Peter Gasser, who conducted the therapy and followed up with his patients a year after the trial concluded.
Submit Comment

[ Cite HTML ]